Allora is a clinical-stage medical device company developing the Allora BreathTest (ABT), a novel drug/device biomarker technology platform that enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its drug substrates via proprietary delivery systems. The Company has established clinical proof-of-concept through trials in cystic fibrosis, tuberculosis and community-acquired pneumonia, which demonstrated positive safety and clinical efficacy results. Allora is planning pivotal trials in ventilator-associated pneumonia and plans to submit an Investigational Device Exemption application to the U.S. FDA for these trial in 2023. Market expansion will address additional bacterial infections including COPD, cystic fibrosis (CF), non CF bronchiectasis, community acquired pneumonia, tuberculosis (TB).
